The estimates of effects with clopidogrel, ticlopidine, and dipyridamole relative to ASA suggest that the therapeutic choice with optimal direct health effects is unclear.
The economic analysis found that for patients who were a mean age of 60 years at the time of their initial stroke, ASA is the most cost-effective treatment option for the secondary prevention
of recurrent stroke. For patients in this age group who do not tolerate ASA, ASA-ERDP may be a cost-effective alternative. For patients aged 70 years or more at the time of their initial stroke,
ASA-ERDP was found to be the most cost-effective treatment option. These conclusions assume a willingness-to-pay threshold of $50,000 per QALY, and are subject to the limitations of the
analysis.